Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Burkitt Lymphoma 25Prostatic Neoplasms 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Large B-Cell, Diffuse 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Leukemia, Biphenotypic, Acute 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Plasmablastic Lymphoma 3Lymphoma, T-Cell 3Lymphoma, Follicular 3Lymphoma 3Hodgkin Disease 3Multiple Myeloma 2Melanoma 2Lymphoma, Large-Cell, Anaplastic 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Blast Crisis 2Vasculitis, Central Nervous System 1Urogenital Neoplasms 1Stiff-Person Syndrome 1Stage II Prostate Adenocarcinoma 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Oropharyngeal Neoplasms 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1

Interventions

Dexamethasone 808Bortezomib 446Lenalidomide 430Cyclophosphamide 336Melphalan 250Calcium Dobesilate 236daratumumab 217pomalidomide 201carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67Prednisone 64dexamethasone 21-phosphate 63isatuximab 62elotuzumab 60auricularum 57Antilymphocyte Serum 55belantamab mafodotin 54Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Multiple Myeloma × deltacortene × Clear all
NCT00602641 2026-04-29

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
306 enrolled 12 charts
Plasma cell

Multiple Myeloma

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

European Myeloma Network B.V.

Phase 2 Completed
150 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡